Skip to main content

Viekira XR FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 25, 2019.

FDA Approved: Yes (Discontinued) (First approved July 22, 2016)
Brand name: Viekira XR
Generic name: dasabuvir, ombitasvir, paritaprevir and ritonavir
Dosage form: Extended-Release Tablets
Company: AbbVie Inc.
Treatment for: Hepatitis C

Marketing Status: Discontinued

Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) is a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor, NS5A inhibitor, NS3/4A protease inhibitor, and CYP3A inhibitor fixed-dose combination indicated for the once-daily treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1 infection.

Development timeline for Viekira XR

Jul 25, 2016Approval AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.